Michael Granieri, MD
Urology · Germantown, TNNPI 1992095541
Payments from drug & device makers
Across 316 payments — averaging $765.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$171K
- Boston Scientific$66K
- Astellas Pharma US Inc$620
- Ferring Pharmaceuticals Inc.$545
- Johnson & Johnson$349
- AbbVie$324
- plus $3K from 31 others
What the payments were for
- Consulting fees$5,1757%
- Speaking & faculty fees$47,96068%
- Travel & lodging$7,59611%
- Food & beverage$10,27514%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 19 | $170,758 |
| Boston Scientific | 121 | $66,169 |
| Astellas Pharma US Inc | 41 | $620 |
| Ferring Pharmaceuticals Inc. | 9 | $545 |
| Johnson & Johnson | 8 | $349 |
| AbbVie | 20 | $324 |
| Endo Pharmaceuticals Inc. | 12 | $322 |
| Medtronic(2 entities) | 3 | $236 |
| Dendreon Pharmaceuticals LLC | 2 | $167 |
| Sumitomo Pharma America, Inc. | 11 | $166 |
| Urogen Pharma, Inc. | 5 | $159 |
| Bayer | 3 | $156 |
| Myovant Sciences Inc. | 12 | $152 |
| Angiodynamics, Inc. | 1 | $151 |
| Janssen Scientific Affairs, LLC | 1 | $150 |
| I/o Urology Corp. | 1 | $150 |
| Teleflex LLC | 2 | $145 |
| Tolmar, Inc. | 1 | $128 |
| Neotract Inc. | 1 | $118 |
| Pfizer | 7 | $118 |
| Blue Earth Diagnostics | 4 | $76 |
| Coloplast | 5 | $69 |
| Novartis | 3 | $66 |
| Axonics, Inc. | 4 | $63 |
| Merck | 2 | $56 |
| Laborie Medical Technologies Corp. | 2 | $52 |
| Telix Pharmaceuticals | 2 | $48 |
| Endo USA, Inc. | 2 | $44 |
| Sun Pharmaceutical Industries Inc. | 2 | $34 |
| Travere Therapeutics, Inc. | 2 | $33 |
| Procept Biorobotics Corporation | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Amgen | 2 | $24 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $15 |
| Accord Healthcare, Inc. | 1 | $15 |
| Sandoz | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TACTRA$21,100
- AdVance XP$8,100
- GENERAL ERECTILE DYSFUNCTION$4,632
- AMS 700 CXR RTE KIT$2,616
- GEMINI$2,400
- AMS 700$1,845
- AMS$995
- Erleada$406
- ADSTILADRIN$272
- UroLift$242
- Nanoknife$151
- CarePath$150
- PROVENGE$148
- AMS 800 Artificial Urinary Sphincter$137
- INTERSTIM$129
- Xofigo$123
- XIAFLEX$115
- AVEED$115
How this compares
$241,764 in reported general payments places this provider in the 90th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 70 | $73,689 |
| OrgovyxRelugolix | 25 | $68,145 |
| MyrbetriqMirabegron | 35 | $42,574 |
| Tamsulosin Hcl | 427 | $7,882 |
| Testosterone | 42 | $4,518 |
| Finasteride | 329 | $3,960 |
| Tolterodine Tartrate ErTolterodine Tartrate | 26 | $2,462 |
| Testosterone Cypionate | 37 | $1,561 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 147 | $1,281 |
| Trospium Chloride ErTrospium Chloride | 13 | $1,084 |
| Oxybutynin Chloride ErOxybutynin Chloride | 26 | $968 |
| Cefdinir | 58 | $859 |
| Dutasteride | 19 | $607 |
| Oxybutynin Chloride | 11 | $572 |
| Doxycycline Monohydrate | 16 | $561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa, Orgovyx | $166 | $141,83495 claims |
| Astellas Pharma US IncMyrbetriq | $620 | $42,57435 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 urology providers in Tennessee.
Other urology in Germantown
- Paul EberGermantown$795K
- Adam StewartGermantown$487K
- Ravi ChauhanGermantown$182K
- William ShappleyGermantown$17K
- William ShappleyGermantown$15K
- John AdamsGermantown$14K
- Gautam JayramNashville$16.1M
- David MorrisHendersonville$7.3M
- David PensonNashville$4.4M
- L KnollNashville$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.